Cargando…

Effects of blocking CD24 and CD47 ‘don't eat me’ signals in combination with rituximab in mantle‐cell lymphoma and chronic lymphocytic leukaemia

Mantle‐cell lymphoma (MCL) is a B‐cell non‐Hodgkin Lymphoma (NHL) with a poor prognosis, at high risk of relapse after conventional treatment. MCL‐associated tumour microenvironment (TME) is characterized by M2‐like tumour‐associated macrophages (TAMs), able to interact with cancer cells, providing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aroldi, Andrea, Mauri, Mario, Ramazzotti, Daniele, Villa, Matteo, Malighetti, Federica, Crippa, Valentina, Cocito, Federica, Borella, Chiara, Bossi, Elisa, Steidl, Carolina, Scollo, Chiara, Voena, Claudia, Chiarle, Roberto, Mologni, Luca, Piazza, Rocco, Gambacorti‐Passerini, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568669/ https://www.ncbi.nlm.nih.gov/pubmed/37654003 http://dx.doi.org/10.1111/jcmm.17868

Ejemplares similares

Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019
por: Aroldi, Andrea, et al.
Publicado: (2021)

Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients
por: Fontana, Diletta, et al.
Publicado: (2023)

DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients
por: Malighetti, Federica, et al.
Publicado: (2023)

A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK(+) lymphomas
por: Rindone, Giovanni, et al.
Publicado: (2022)

An Imatinib–non‐responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization
por: Crespiatico, Ilaria, et al.
Publicado: (2019)

Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
por: Inzoli, Elena, et al.
Publicado: (2022)

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
por: Sharma, Geeta Geeta, et al.
Publicado: (2018)

Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling
por: Ceccon, Monica, et al.
Publicado: (2018)

P1235: INVESTIGATION OF THE CO-MUTATIONAL LANDSCAPE OF ALK-POSITIVE ALCL
por: Villa, Matteo, et al.
Publicado: (2023)

P1175: THROMBOTIC RISK IN DLBCL: A REAL-LIFE COMPARISON OF THE THROLY AND MODEL IX SCORES
por: Civettini, Ivan, et al.
Publicado: (2023)

Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID‐19 vaccine: A single‐center prospective observational study (NCT05074706)
por: Bossi, Elisa, et al.
Publicado: (2022)

NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
por: Mologni, Luca, et al.
Publicado: (2015)

Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells
por: Mologni, Luca, et al.
Publicado: (2012)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Regulation of CD45 phosphatase by oncogenic ALK in anaplastic large cell lymphoma
por: Mura, Giulia, et al.
Publicado: (2023)

Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2021)

Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns
por: Riccardo, Federica, et al.
Publicado: (2017)

VERSO: A comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples
por: Ramazzotti, Daniele, et al.
Publicado: (2021)

The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition
por: Mologni, Luca, et al.
Publicado: (2017)

Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea
por: Renso, Rossella, et al.
Publicado: (2018)

Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma
por: Arosio, Giulia, et al.
Publicado: (2021)

Characterization of SARS-CoV-2 Mutational Signatures from 1.5+ Million Raw Sequencing Samples
por: Aroldi, Andrea, et al.
Publicado: (2022)

RHO Family GTPases in the Biology of Lymphoma
por: Voena, Claudia, et al.
Publicado: (2019)

Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia
por: Gambacorti‐Passerini, Carlo, et al.
Publicado: (2022)

TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells
por: Cordani, Nicoletta, et al.
Publicado: (2023)

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
por: Fontana, Diletta, et al.
Publicado: (2021)

Targeting CD83 in mantle cell lymphoma with anti‐human CD83 antibody
por: Li, Ziduo, et al.
Publicado: (2020)

OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes
por: Rocco, Piazza, et al.
Publicado: (2017)

Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes
por: Piazza, Rocco, et al.
Publicado: (2017)

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
por: Redaelli, Sara, et al.
Publicado: (2016)

ERG Deregulation Induces PIM1 Over-Expression and Aneuploidy in Prostate Epithelial Cells
por: Magistroni, Vera, et al.
Publicado: (2011)

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells()
por: Mologni, Luca, et al.
Publicado: (2018)

Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia
por: Fontana, Diletta, et al.
Publicado: (2020)

High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis
por: Li, Philippa, et al.
Publicado: (2021)

P1056: NEXT GENERATION SEQUENCING IDENTIFIES SUBGROUPS OF PATIENTS WITH TRIPLE NEGATIVE/ PRIMARY THROMBOCYTOSIS WITH DIFFERENT CLINICAL OUTCOMES
por: Sangiorgio, Valentina, et al.
Publicado: (2023)

CXCR4 engagement triggers CD47 internalization and antitumor immunization in a mouse model of mesothelioma
por: Mezzapelle, Rosanna, et al.
Publicado: (2021)

In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib
por: Redaelli, Sara, et al.
Publicado: (2015)

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi
por: Zamprogna, Giulia, et al.
Publicado: (2023)

CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma
por: Freile, Jimena Álvarez, et al.
Publicado: (2022)

The “don't eat me” signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma
por: Schürch, Christian M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2qfthh8aipgjb1vvae8tdr54gd